Edwards Lifesciences Corp (NYSE:EW) Position Reduced by Rosenbaum Jay D.

Rosenbaum Jay D. decreased its holdings in Edwards Lifesciences Corp (NYSE:EW) by 6.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 9,160 shares of the medical research company’s stock after selling 627 shares during the period. Edwards Lifesciences makes up about 3.2% of Rosenbaum Jay D.’s investment portfolio, making the stock its 7th largest position. Rosenbaum Jay D.’s holdings in Edwards Lifesciences were worth $1,692,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. FTB Advisors Inc. acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $25,000. TRUE Private Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $26,000. Evolution Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. M&R Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. Finally, Field & Main Bank acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $34,000. Hedge funds and other institutional investors own 82.43% of the company’s stock.

A number of brokerages recently weighed in on EW. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Credit Suisse Group lifted their price objective on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a research note on Wednesday, July 24th. BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Finally, Barclays lifted their price objective on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research note on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $204.74.

Edwards Lifesciences stock traded up $3.30 during midday trading on Thursday, hitting $216.81. The company’s stock had a trading volume of 25,008 shares, compared to its average volume of 1,186,828. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.38 and a quick ratio of 2.48. The business’s 50-day simple moving average is $200.64. Edwards Lifesciences Corp has a 12 month low of $134.53 and a 12 month high of $219.71. The firm has a market capitalization of $44.90 billion, a P/E ratio of 45.96, a PEG ratio of 2.72 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.33 by $0.05. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. Edwards Lifesciences’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.24 earnings per share. As a group, equities analysts predict that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,369 shares of Edwards Lifesciences stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $175.06, for a total transaction of $939,897.14. Following the transaction, the vice president now owns 26,043 shares of the company’s stock, valued at approximately $4,559,087.58. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Larry L. Wood sold 6,716 shares of Edwards Lifesciences stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $169.75, for a total value of $1,140,041.00. Following the transaction, the vice president now directly owns 124,102 shares in the company, valued at approximately $21,066,314.50. The disclosure for this sale can be found here. Insiders sold a total of 142,948 shares of company stock worth $27,936,332 in the last three months. 1.63% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Calculating net profit and net profit margin ratio

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.